医学
阿利罗库单抗
急性冠脉综合征
PCSK9
前蛋白转化酶
内科学
心肌梗塞
枯草杆菌素
可欣
他汀类
Evolocumab公司
心脏病学
胆固醇
脂蛋白
载脂蛋白A1
酶
化学
生物化学
低密度脂蛋白受体
作者
Gregory G. Schwartz,Ph. Gabriel Steg,Michael Szarek,Deepak L. Bhatt,Vera Bittner,Rafael Dı́az,Jay M. Edelberg,Shaun G. Goodman,Corinne Hanotin,Robert A. Harrington,J. Wouter Jukema,Guillaume Lecorps,Kenneth W. Mahaffey,Angèle Moryusef,Robert Pordy,Kirby Quintero,Matthew T. Roe,William J. Sasiela,Jean-François Tamby,Pierluigi Tricoci,Harvey D. White,Andreas M. Zeiher
标识
DOI:10.1056/nejmoa1801174
摘要
Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI